Lannett adds Silarx's liquid manufacturing to its operations

Philadelphia-based generic maker Lannett says it has beefed up its manufacturing, and its generic portfolio, with the acquisition of Silarx for an undisclosed amount. Silarx specializes in liquid products, both generic prescriptions and over-the-counter, which it manufactures at its 110,000-square-foot facility in Carmel, NY. "Upon closing, the acquisition will add a high quality, talented research team and manufacturing capacity," Lannett CEO Arthur Bedrosian said in a statement. Release

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.